Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States gptkb:FDA |
| gptkbp:ATCCode |
L01EX25
|
| gptkbp:brand |
Lytgobi
|
| gptkbp:CASNumber |
1448169-86-9
|
| gptkbp:chemicalClass |
quinazoline derivative
|
| gptkbp:developer |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:hasMolecularFormula |
C22H20FN5O3
|
| gptkbp:hasSMILES |
C1=CC=C2C(=C1)N=C(N=C2N)NCC3=CC(=C(C=C3)F)C(=O)NC4=CC=CC=C4C(=O)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
futibatinib
|
| gptkbp:indication |
unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:PubChem_CID |
71587768
CHEMBL3989949 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue alopecia hyperphosphatemia nail toxicity stomatitis |
| gptkbp:target |
gptkb:FGFR2
|
| gptkbp:UNII |
6Q1K1Q1K0F
|
| gptkbp:usedFor |
cholangiocarcinoma
|
| gptkbp:bfsParent |
gptkb:FGFR1
|
| gptkbp:bfsLayer |
6
|